28 July 2017 Fluorescently labeled bevacizumab in human breast cancer: defining the classification threshold
Author Affiliations +
Abstract
In-vivo fluorescently labelled drug (bevacizumab) breast cancer specimen where obtained from patients. We propose a new structured method to determine the optimal classification threshold in targeted fluorescence intra-operative imaging.
© (2017) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Maximilian Koch, Johannes S. de Jong, Jürgen Glatz, Panagiotis Symvoulidis, Laetitia E. Lamberts, Arthur L. L. Adams, Mariëtte E. G. Kranendonk, Anton G. T. Terwisscha van Scheltinga, Michaela Aichler, Liesbeth Jansen, Jakob de Vries, Marjolijn N. Lub-de Hooge, Carolien P. Schröder, Annelies Jorritsma-Smit, Matthijs D. Linssen, Esther de Boer, Bert van der Vegt, Wouter B. Nagengast, Sjoerd G. Elias, Sabrina Oliveira, Arjen J. Witkamp, Willem P. Th. M. Mali, Elsken Van der Wall, P. Beatriz Garcia-Allende, Paul J. van Diest, Elisabeth G. E. de Vries, Axel Walch, Gooitzen M. van Dam, Vasilis Ntziachristos, "Fluorescently labeled bevacizumab in human breast cancer: defining the classification threshold", Proc. SPIE 10411, Clinical and Preclinical Optical Diagnostics, 104110F (28 July 2017); doi: 10.1117/12.2286062; https://doi.org/10.1117/12.2286062
PROCEEDINGS
4 PAGES


SHARE
Back to Top